ArticleBreast cancer research : BCR2026
The association between adiposity and cardiac function in patients with early breast cancer receiving cardiotoxic therapies.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAnthracyclines and HER2-directed therapies improve survival in early breast cancer but increase cardiovascular risk, which body mass index poorly characterizes. We evaluated longitudinal associations between pre-treatment CT-derived body composition and echocardiography-derived systolic and diastolic function in a prospective cohort of women with early breast cancer.
methodsIn a prospective cohort of women with stage I-III early breast cancer treated with anthracyclines and/or trastuzumab, skeletal muscle index (SMI), muscle density (SMD), and visceral and subcutaneous adipose tissue area and density (VAT, SAT, VATD, SATD) were quantified from pre-treatment CT or PET-CT at L3 using automated segmentation. Longitudinal changes in LVEF and E/e' were analyzed using multivariable-adjusted GEE models. Time to incident systolic dysfunction (≥ 10% LVEF decline to < 50%) and diastolic dysfunction (E/e' ≥ 14) were analyzed using Cox proportional hazards models.
resultsAcross 177 participants (median age 50 years, 36.2% HER2-positive, 19.9% triple-negative), 145 (81.9%) received anthracycline-based therapy. Baseline body composition was not associated with longitudinal LVEF change. Higher baseline VAT (β 0.6, 95% CI 0.2-0.9; p = 0.001) and VAT/SAT ratio (β 0.5, 95% CI 0.2-0.7; p < 0.001) were associated with increased E/e' over time, while higher VATD (β - 0.4, 95% CI - 0.6 to - 0.1; p = 0.002) was associated with decreased E/e' during follow-up. No associations were observed for SAT or SATD.
conclusionsPre-treatment visceral adiposity is associated with worsening diastolic function during breast cancer therapy. CT-derived body composition may refine cardiotoxicity risk assessment beyond BMI.
Indexed as
Identifiers
42482141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.